Class: Histamine H2 receptor antagonist (H2 blocker) MOA: Competitive, reversible blockade of histamine H2 receptors on gastric parietal cells. By blocking H2 receptors, ranitidine prevents histamine-stimulated formation of cAMP, reducing proton pump activity and thereby decreasing basal and meal-stimulated gastric acid secretion (including nocturnal acid secretion). It does not block acetylcholine or gastrin receptors.

Ask Questions, Get Industry Insights … Instantly

Save time and get answers to complex questions with AI chat

Recent Questions

Tenofovir generic patent?
Combivent inhaler hfc 152a patents?
Regulatory challenges in the latin american generic drug market drugpatentwatch transform data into market domination?
Patent tenofovir alafenamide gilead?
When will latisse patent expire?

Ranitidine moa?

See the DrugPatentWatch profile for Ranitidine

Class: Histamine H2 receptor antagonist (H2 blocker)
MOA: Competitive, reversible blockade of histamine H2 receptors on gastric parietal cells. By blocking H2 receptors, ranitidine prevents histamine-stimulated formation of cAMP, reducing proton pump activity and thereby decreasing basal and meal-stimulated gastric acid secretion (including nocturnal acid secretion). It does not block acetylcholine or gastrin receptors.